Introduction
End stage liver disease associated with chronic HCV infection is a leading indication for liver transplantation 1 . Unfortunately, reinfection of the donor organ is universal. In fact, 20-25% of graft recipients develop cirrhosis within 5 years and the survival of HCV-positive patients is lower compared to HCV-negative recipients 2, 3 . Current antiviral treatment of chronic HCV infection is based on PEG-IFN-and ribavirin and is limited by side effects and suboptimal response rates particularly in difficult-to-treat transplant patients 4 . First generation of directly acting antivirals which target the viral NS3-4A protease have improved treatment options.
However, resistance development 5 and viral genotype-specific efficacy 6 of these drugs necessitate alternative antiviral treatment options. Therefore, new therapeutics that eliminate chronic virus replication, prevent progression to end stage liver disease or preclude reinfection of the donor organ in HCV-associated orthotopic liver transplantation could provide a substantial benefit.
HCV is a highly variable, hepatotropic RNA virus that establishes a chronic infection in the majority of cases. Viral strains are grouped into six major genotypes that differ from each other by more than 30% at the nucleotide level 7 . The variability of HCV permits immune evasion and thus facilitates viral persistence. It is also a challenge for development of specific antiviral therapies active against all viral genotypes and for prevention of drug resistance.
Recently, cell culture systems reproducing the complete replication cycle of HCV have been developed 8 and utilized to define novel drug targets and to identify and characterize new antiviral compounds. These studies, for instance, revealed an essential role of four host derived proteins, the scavenger receptor class B type I (SR-BI), CD81, claudin-1 (CLDN1) and occludin (OCLN) for productive cell entry by HCV 9 . In turn, interference with the early steps of HCV infection, which are essential for spread and maintenance of HCV infection, has emerged as attractive target for development for novel therapeutic options 10 . In parallel, several natural flavonoids including silibinins, silymarin and naringenin, which interfere with HCV propagation by targeting the viral polymerase 11 or by alternative mechanisms likely also involving host-derived factors, have recently been identified [12] [13] [14] and thus have highlighted compounds with flavonoid scaffold as attractive molecules for HCV drug development.
Importantly, HCV liver graft reinfection was recently successfully prevented by silibinin monotherapy 15 . These promising advances prompted us to screen various polyphenolic compounds and glycosides for novel inhibitors of HCV infection.
Material and Methods

Synthesis of BJ486K
The total synthesis of BJ486K was developed according to the known procedure 16 with slight modifications. The full details of the total synthesis will be described in a further manuscript, as part of a physicochemistry analysis. The chemical analysis was in agreement with that of the natural compound, ladanein (Supplementary Figure S2) .
Cell Culture
Huh7-Lunet/CD81 cells, a derivative of Huh-7 cells highly permissive for HCV RNA replication and infection 17 , were cultured in Dulbecco`s modified Eagle medium (DMEM, Invitrogen) with 10% fetal bovine serum (FCS Gold, PAA, Coelbe, Germany), 1x nonessential amino acids (Invitrogen), 100 µg/ml streptomycin (Invitrogen) and 100 IU/ml penicillin (Invitrogen) , 2 mM L-glutamine (Invitrogen) and 750 µg/ml geneticin (Carl Roth, Germany).
In vitro transcription and electroporation of Huh7-Lunet/CD81 cells
In vitro transcripts were generated and transfected using electroporation as described recently 18 .
Luciferase infection assay
Huh7-Lunet/CD81 cells were infected with reporter virus particles essentially as described recently 18 . Briefly, for inoculation with firefly luciferase reporter virus particles (Luc-Jc1
18
) and renilla reporter viruses (JcR-2a 19 and GT1-6, this study), Huh7-Lunet/CD81 cells were seeded at a density of 6×10e4 cells per well of a 12-well plate or 6.6×10e3 cells per well of a 96-well plate 24h prior to inoculation. If not stated otherwise, the virus particles were pretreated with the inhibitors for 1h at 37°C. Cells were inoculated for 4h at 37°C, viral inoculum was replaced by fresh culture fluid and infection was quantified 48h or 72h after virus inoculation using luciferase assays. 
Freeze and thaw lysis of HCV-transfected cells
Huh7-Lunet/CD81 cells were transfected with Jc1 RNA and seeded on a 6-well plate.
Compounds were added 4h later. At 48h after transfection, cell culture supernatant was harvested and used for measuring the extracellular core amount. Cells were washed once with PBS, scraped and centrifuged for 5 min at 1000×g. Cell pellets were resuspended in 500 µl fresh culture fluid and subjected to three cycles of freeze and thaw using liquid nitrogen and a 37°C thermo block. Samples were than centrifuged at 10,000xg for 10 min to remove cell debris and the core amount was measured (intracellular core protein) using the ARCHITECT HCV Core AG test (Abbott, Wiesbaden, Germany) according to the instructions of the manufacturer.
Cytotoxicity assay
Cytotoxicity was measured using the CytoTox-Glo cytotoxicity assay (Promega, Mannheim, Germany) as described by the manufacturer employing a plate luminometer Centro XS LB960 (Berthold, Freiburg, Germany) according to the manufacturer´s instructions.
Determination of antiviral activity against early steps of HCV cell entry
JcR-2a virus particles were incubated with Huh7-Lunet/CD81 cells seeded as described above for 1h at 4°C to synchronize cell entry. Various inhibitors including 50 µg/ml heparin (Sigma-Aldrich), CD81-specific antibody JS-81 (2 µg/ml; Becton Dickinson), ITX 5061 (10 µM) or BJ486K (20 µM), were added during virus inoculation (protocol 1) or at indicated time points after virus inoculation (protocol 2-8). After 4h inhibitor treatment, medium was changed to fresh culture fluid without inhibitors and the cells were lysed 48h after inoculation as described above. Efficiency of infection was determined by luciferase assay using a tube luminometer (Lumat LB9507, Berthold, Freiburg, Germany).
Immunohistochemical staining and virus titration
Virus titers were measured using the limiting dilution assay as described recently 20 . Virus titers (50% tissue culture infective dose [TCID 50 /ml]) were calculated based on the method of Spearman and Kärber 21, 22 .
Infection of primary human hepatocytes
Normal-appearing liver tissue from patients seronegative for HCV, hepatitis B virus, and human immunodeficiency virus (HIV) was obtained from adult patients undergoing partial hepatectomy for the therapy of metastases. Experimental procedures were carried out in accordance with French Laws and Regulations. Hepatocytes were isolated by a two-step perfusion technique and maintained in primary culture as described previously 23 . Cells were inoculated with Con1/C3-HCV 24 grown in Huh-7.5.1 cells at a multiplicity of infection of 0.1 in the presence of dimethylsulfoxide as carrier control, or else increasing concentrations of BJ486K. Three days later, infectivity titers in culture supernatants as well as HCV RNA amounts were determined by focus-formation assay or qRT-PCR analysis respectively as previously described 23, 25 .
Results
Identification of a flavonoid with antiviral activity against HCV
To identify novel bioactive molecules with antiviral activity, a bio-guided fractionation was performed starting from a Lamiaceae plant, a Marrubium species reported to be rich in flavone aglycones, flavone glycosides, coumaroylated flavone glycosides and acteosiderelated phenylethanoids 26 . Natural phenolic compounds were isolated from plant extracts of 
BJ486K inhibits HCV cell entry but not RNA replication or virus production
Our screening assay does not distinguish which step of the HCV replication cycle is affected by a given compound. Therefore, to characterize the antiviral effect of BJ486K, we next assessed the impact of BJ486K on the steps of HCV RNA translation and replication. To this end, we transfected Huh7-Lunet/CD81 cells with a subgenomic JFH1 luciferase replicon and monitored RNA replication 72h later by luciferase assays. As control we incubated the cells with increasing doses of the NS3-4A protease inhibitor boceprevir and the polymerase inhibitor 2´-C-methyladenosine (2´CMA). As shown in Figure 3A , BJ486K affected neither RNA translation nor replication of HCV RNA as luciferase activity was not changed up to a dose of 10µM.
To determine whether BJ486K affects virus assembly or release we transfected Huh7-Lunet/CD81 cells with Jc1 RNA and quantified intra-and extracellular levels of core protein 48h after transfection ( Figure 3B ). As expected, both quinidine and the grapefruit flavonoid naringenin, two assembly inhibitors recently identified using the JFH1-based infection system 14, 27 , selectively reduced extracellular levels of core protein by more than 100-or ca.
5-fold, respectively, thus confirming their interference with HCV virus production. In contrast, BJ486K reduced neither intracellular nor extracellular core protein levels up to a dose of 20 µM, which is 10-fold higher than the determined EC50 value ( Figure 2 ). Collectively these data indicate that different flavonoids can prevent HCV propagation by distinct mechanisms and that BJ486K does not impede HCV RNA translation, RNA replication and virus production. In agreement with this conclusion, addition of BJ486K only interfered with HCV infection when the drug was present during virus inoculation, whereas addition of the compound before or after virus inoculation did not preclude productive cell entry and subsequent RNA replication ( Figure 3C ).
BJ486K interferes with a post-attachment step of HCV cell entry
To resolve which step of HCV cell entry is inhibited by BJ486K, we assessed its antiviral activity when administered at different time points during the early phase of infection. To this end, Huh7-Lunet/CD81 cells were inoculated for one hour at 4°C with a reporter virus prepared in the absence of drugs. At this temperature, virus particles bind to the cell surface but do not efficiently enter, thus permitting a rather synchronous infection when the inoculum is removed and cells are shifted to 37°C. A selection of HCV entry inhibitors which prevent infection by different mechanisms or BJ486K were added during inoculation, directly afterwards or at different intervals shortly thereafter. To attain maximal sensitivity we used a novel monocistronic renilla luciferase reporter virus based on the intragenotypic genotype 2a chimera Jc1 which is designated JcR-2a and that was described recently 19 ( Figure 4 ). As expected, heparin which is known to impede HCV cell attachment 
BJ486K is not affected by viral resistance against a SR-BI-targeting entry inhibitor, inhibits HCV of all major genotypes and impedes infection of primary human hepatocytes
Syder et al. recently reported that a specific mutation within the HCV envelope protein E2 (G451R) that is known to reduce viral dependency on SR-BI for cell entry 29 at the same time reduces the susceptibility of HCV towards inhibition by ITX5061 28 . These data indicate that decrease of SR-BI receptor dependence by HCV is a possible viral escape mechanism from inhibition by SR-BI-targeting antivirals. Therefore, to explore whether this viral resistance mechanism also compromises the antiviral activity of BJ486K we compared the antiviral activity of the two compounds against wild type and the mutant virus carrying the G451R exchange within E2. In line with the report by Syder et al., the aforementioned mutation rendered HCV resistant to inhibition by ITX5061 ( Figure 5A ). In contrast, the antiviral activity of BJ486K was not changed by this mutation ( Figure 5B Therefore, we determined the antiviral activity of BJ486K towards HCV particles from different genotypes. To be able to resolve different response rates among these viruses with highest resolution, we created a set of novel reporter virus constructs based on the JcR-2a backbone ( Figure 4 ). Importantly, antiviral activity of BJ486K against cell culture derived particles from genotype 1a, 1b, 2b, 3a, 4a, 5a and 6a was comparable and showed an EC50 below 4.2 µM indicating that BJ486K inhibits HCV cell entry independently of viral genotype or subtype ( Figure 5C and Supplementary Table 1) .
Although human hepatocellular carcinoma derived cell lines sustain the entire HCV replication cycle and are a well-accepted model for HCV infection studies, these cells nevertheless functionally differ from primary human hepatocytes. Therefore, to confirm the antiviral activity of BJ486K in a more natural system, primary human hepatocytes were inoculated in the presence or absence of BJ486K with a cell culture derived genotype 1b virus (Con1/C3; 24 ). As shown in Figure 5D , Con1/C3 infection of primary human hepatocytes was inhibited by BJ486K in a dose-dependent fashion with an EC50 value of ca. 10µM. Collectively, our data highlight a novel flavone with potent and broad-spectrum antiviral activity against HCV. These findings should encourage further development of flavonederived compounds as attractive pan-genotype entry inhibitors for treatment of HCV.
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Infection assays with HIV, vesicular stomatitis virus, adenovirus and coxsackievirus
Env-deleted HIV-1-GFP reporter viruses, which had been pseudotyped with the R5 envelope from YU-2, were incubated with the indicated concentrations of either BJ486K or MP03
(Supplementary Figure 4) for 1h at 37°C, in principle as reported .
Evaluation of bioavailability in mice.
Mice (24 in total) were treated either orally or intraveniously with a single dose of 0.25 mg/kg of the inhibitor (solved in saline/10% cremophor EL). At different time points after inhibitor administration (5 min, 15 min, 30 min, 60 min, 120 min or 180 min) two mice from each group were sacrified and the blood was centrifuged to obtain the plasma, which was stored at -80°C until further examination.
400 µl of each plasma sample was mixed with equal amount of a 2% trifluoroacetic acid and loaded on a SPE Strata C18 column (equilibrated with 1 ml methanol and 1 ml 1% trifluoroacetic acid) for solid phase extraction of the plasma. After several washing steps (1% trifluoroacetic acid and water), the samples were eluted with acetonitrile and dried. The remaining sample was resolved in 25 µl acetonitrile:water (ratio 1:1). Samples were further analyzed with a LC-MS/MS (triple quadrupole mass spectrometer LCMS 8030 Shimadzu), which was calibrated at the day of measurement. Plasma drug concentrations versus time curves were plotted for each route. Bioavailability was calculated by dividing the area under curve (AUC) for oral route by the AUC for intravenous route.
Supplementary Table 1 : Antiviral activity of BJ486K across all major HCV genotypes Figure S1 : Structures of polyphenolic compounds analysed in this work. All compounds depicted were screened for antiviral activity against HCV using the screening system described in Figure 1 . The short name of the extract containing the respective compound as dominant species is given along with the chemical name of the compound. (AdV5) was determined using limiting dilution assays.
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